Skip to content

Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica

A Corticosteroid Taper for Acute Sciatica Treatment (The ACT FAST Study)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00668434
Acronym
ACT FAST
Enrollment
269
Registered
2008-04-29
Start date
2008-11-30
Completion date
2013-09-30
Last updated
2015-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sciatica

Keywords

Back Pain, Leg Pain

Brief summary

Sciatica is a condition that causes a sharp, burning pain in the back, buttock, and leg. The condition is caused by injury to or compression of the sciatic nerve, which is located in the back of the leg. This study will determine the effectiveness of the steroid prednisone in decreasing pain and improving function in people with sciatica.

Detailed description

Sciatica is most often caused by a herniated disc in the lumbar region of the back and results from inflammation of the nerve roots as they exit the spine. It is a very common cause of back and leg pain, loss of function, and inability to work. Although sciatica is common, the effectiveness of current treatments is limited. Epidural steroid injections (ESIs), which can reduce inflammation of the nerve roots, are commonly used to decrease sciatica pain and restore normal function in patients. The exact effectiveness of ESIs, however, is unknown. If inflammation, and not compression, is the main cause of sciatica, it is reasonable to consider giving the steroid orally rather than by injection. If oral steroids prove effective, patients and clinicians will have access to a simple, inexpensive therapy that can be prescribed by primary care physicians without delay. This study will determine the effectiveness of the oral steroid prednisone in decreasing pain and improving function in people with sciatica. Participants in this study will attend a screening visit at which they will answer questions about their health to determine eligibility, undergo a neurologic exam, and have a plain lower spine x-ray. An MRI of the lower spine will be performed for those who meet clinical eligibility. Participants whose MRI shows that a disc has ruptured in a specific way will be randomly assigned to receive either a 15-day course of prednisone capsules or a 15-day course of placebo capsules. Participants will take their assigned study medications in addition to their usual pain medications. At Week 3, participants will return for a follow-up visit during which they will answer questions about their pain and general health and wellness. Participants who are still having considerable pain will be offered an epidural steroid injection (ESI) as a part of the study. At Week 6, participants will be called at home for a telephone interview and again answer questions about their general health and wellness; this telephone call will last about 20 minutes. If they continue to have considerable pain, they will be offered a second ESI as part of the study. At Week 12, an interviewer will phone participants to determine if their pain has decreased and whether they have been able to return to their normal activities. The telephone contact will last about 20 minutes. Additional information about their back problems will be obtained from their medical records and from Kaiser Permanente's computerized medical records on their use of health care and medicines for back problems. At Week 24, participants will attend an evaluation visit at the Spine Clinic to assess their progress and symptoms. At Week 52 (1 year from randomization), participants will undergo a final telephone interview.

Interventions

DRUGPrednisone

For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.

DRUGPlacebo

Placebo capsules will look the same as the study medication but will not contain active medicine.

Sponsors

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
CollaboratorNIH
Kaiser Permanente
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Seeks care at a Kaiser Permanente clinic spine care specialist at the San Jose, Redwood City, or Roseville site * Complains of low back pain and functionally incapacitating leg pain extending below the knee with a nerve root distribution * Score of at least 20 on the modified Oswestry Disability Index * Appears, in the opinion of the study physician, to be very likely to have a herniated lumbar disc * MRI study confirms a herniated disc consistent with the signs and symptoms

Exclusion criteria

* Onset of sciatica symptoms occurred more than 3 months before study entry * Cauda equina syndrome * Active cancer * Acute spinal fracture * Currently taking oral steroids * Diabetes mellitus and taking insulin or glycohemoglobin greater than 10% * Systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg * Pregnant or breastfeeding * Active peptic ulcer disease * History of intolerance to steroid therapy * Bleeding diathesis or anticoagulant therapy * Ongoing litigation or workers compensation claim for low back pain or sciatica * Underwent previous lumbar surgery * Received epidural steroid injection (ESI) within the 12 months before study entry * Unable to read or speak English * Progressive or severe motor loss

Design outcomes

Primary

MeasureTime frameDescription
Oswestry Disability Index, v2Baseline, Week 3 follow-upThe Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.

Secondary

MeasureTime frameDescription
Pain Numerical Rating ScaleBaseline, Week 3 follow-upOrdinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.
Oswestry Disability Index, v2Baseline, Week 52 follow-upThe Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.

Countries

United States

Participant flow

Participants by arm

ArmCount
Prednisone
Participants will receive a 15-day tapering course of prednisone capsules. Prednisone: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
181
Placebo
Participants will receive a 15-day course of placebo capsules. Placebo: Placebo capsules will look the same as the study medication but will not contain active medicine.
88
Total269

Baseline characteristics

CharacteristicTotalPrednisonePlacebo
Age, Continuous46.0 years
STANDARD_DEVIATION 12.1
45.6 years
STANDARD_DEVIATION 11.8
46.7 years
STANDARD_DEVIATION 12.6
Ethnicity (NIH/OMB)
Hispanic or Latino
62 Participants34 Participants28 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
207 Participants147 Participants60 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
5 Participants1 Participants4 Participants
Race (NIH/OMB)
Asian
32 Participants24 Participants8 Participants
Race (NIH/OMB)
Black or African American
6 Participants3 Participants3 Participants
Race (NIH/OMB)
More than one race
19 Participants10 Participants9 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
2 Participants2 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
26 Participants12 Participants14 Participants
Race (NIH/OMB)
White
179 Participants129 Participants50 Participants
Region of Enrollment
United States
269 participants181 participants88 participants
Sex: Female, Male
Female
120 Participants83 Participants37 Participants
Sex: Female, Male
Male
149 Participants98 Participants51 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
143 / 18163 / 88
serious
Total, serious adverse events
3 / 1812 / 88

Outcome results

Primary

Oswestry Disability Index, v2

The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.

Time frame: Baseline, Week 3 follow-up

ArmMeasureValue (MEAN)Dispersion
PrednisoneOswestry Disability Index, v2-19.0 units on a scaleStandard Error 1.4
PlaceboOswestry Disability Index, v2-13.3 units on a scaleStandard Error 1.7
Secondary

Oswestry Disability Index, v2

The Oswestry Disability Index, v2 is a back-pain-specific measure of disability and functional status. It is measured on a 0-to-100 scale, with higher numbers indicating greater disability.

Time frame: Baseline, Week 52 follow-up

ArmMeasureValue (MEAN)Dispersion
PrednisoneOswestry Disability Index, v2-37.8 units on a scaleStandard Error 1.5
PlaceboOswestry Disability Index, v2-30.4 units on a scaleStandard Error 2.2
Secondary

Pain Numerical Rating Scale

Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.

Time frame: Baseline, Week 3 follow-up

ArmMeasureValue (MEAN)Dispersion
PrednisonePain Numerical Rating Scale-3.0 units on a scaleStandard Error 0.2
PlaceboPain Numerical Rating Scale-2.8 units on a scaleStandard Error 0.3
Secondary

Pain Numerical Rating Scale

Ordinal scale of average level of pain as perceived by the participant over the prior 3 days; measured on a 0-to-10 scale, with higher numbers indicating greater pain.

Time frame: Baseline, Week 52 follow-up

ArmMeasureValue (MEAN)Dispersion
PrednisonePain Numerical Rating Scale-5.2 units on a scaleStandard Error 0.2
PlaceboPain Numerical Rating Scale-4.6 units on a scaleStandard Error 0.3

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026